Does the media refer more to NKTR or CYTK?

In the previous week, Cytokinetics had 8 more articles in the media than Nektar Therapeutics. MarketBeat recorded 17 mentions for Cytokinetics and 9 mentions for Nektar Therapeutics. Cytokinetics' average media sentiment score of 0.82 beat Nektar Therapeutics' score of 0.77 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or NKTR?

In the previous week, Protagonist Therapeutics had 12 more articles in the media than Nektar Therapeutics. MarketBeat recorded 21 mentions for Protagonist Therapeutics and 9 mentions for Nektar Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.45 beat Nektar Therapeutics' score of 0.77 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 18 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCVX or NKTR?

In the previous week, Vaxcyte had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 14 mentions for Vaxcyte and 9 mentions for Nektar Therapeutics. Vaxcyte's average media sentiment score of 1.53 beat Nektar Therapeutics' score of 0.77 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NKTR or IMVT?

In the previous week, Immunovant had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 10 mentions for Immunovant and 9 mentions for Nektar Therapeutics. Immunovant's average media sentiment score of 1.25 beat Nektar Therapeutics' score of 0.77 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IBRX or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 9 mentions for Nektar Therapeutics and 8 mentions for ImmunityBio. Nektar Therapeutics' average media sentiment score of 0.77 beat ImmunityBio's score of 0.61 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nektar Therapeutics (NKTR) Competitors

$72.52 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$73.02 +0.50 (+0.69%)

As of 04:12 AM Eastern

Compare

NKTR vs. CYTK, PTGX, PCVX, IMVT, and IBRX

Should you buy Nektar Therapeutics stock or one of its competitors? Nektar Therapeutics's main competitors and comparable companies include Cytokinetics (CYTK), Protagonist Therapeutics (PTGX), Vaxcyte (PCVX), Immunovant (IMVT), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nektar Therapeutics compare to Cytokinetics?

Nektar Therapeutics (NASDAQ:NKTR) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

75.9% of Nektar Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nektar Therapeutics has higher earnings, but lower revenue than Cytokinetics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A
Cytokinetics	$88.04M	101.89	-$784.96M	-$7.22	N/A

Nektar Therapeutics presently has a consensus price target of $141.50, indicating a potential upside of 95.12%. Cytokinetics has a consensus price target of $102.20, indicating a potential upside of 41.77%. Given Nektar Therapeutics' higher possible upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Nektar Therapeutics has a net margin of -287.84% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Cytokinetics	-1,321.12%	N/A	-51.01%

In the previous week, Cytokinetics had 8 more articles in the media than Nektar Therapeutics. MarketBeat recorded 17 mentions for Cytokinetics and 9 mentions for Nektar Therapeutics. Cytokinetics' average media sentiment score of 0.82 beat Nektar Therapeutics' score of 0.77 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

Summary

Cytokinetics beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Protagonist Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Protagonist Therapeutics currently has a consensus target price of $140.53, suggesting a potential downside of 2.63%. Nektar Therapeutics has a consensus target price of $141.50, suggesting a potential upside of 95.12%. Given Nektar Therapeutics' higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Protagonist Therapeutics has a net margin of 29.40% compared to Nektar Therapeutics' net margin of -287.84%. Protagonist Therapeutics' return on equity of 12.03% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

In the previous week, Protagonist Therapeutics had 12 more articles in the media than Nektar Therapeutics. MarketBeat recorded 21 mentions for Protagonist Therapeutics and 9 mentions for Nektar Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.45 beat Nektar Therapeutics' score of 0.77 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	18 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	202.95	-$130.15M	$1.03	140.13
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A

Summary

Protagonist Therapeutics beats Nektar Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Nektar Therapeutics has higher revenue and earnings than Vaxcyte. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A

Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

In the previous week, Vaxcyte had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 14 mentions for Vaxcyte and 9 mentions for Nektar Therapeutics. Vaxcyte's average media sentiment score of 1.53 beat Nektar Therapeutics' score of 0.77 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Vaxcyte's return on equity of -37.56% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 43.74%. Nektar Therapeutics has a consensus target price of $141.50, indicating a potential upside of 95.12%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vaxcyte and Nektar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Immunovant?

Nektar Therapeutics (NASDAQ:NKTR) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Nektar Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

In the previous week, Immunovant had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 10 mentions for Immunovant and 9 mentions for Nektar Therapeutics. Immunovant's average media sentiment score of 1.25 beat Nektar Therapeutics' score of 0.77 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Immunovant	N/A	-69.59%	-62.49%

Nektar Therapeutics currently has a consensus target price of $141.50, suggesting a potential upside of 95.12%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 6.80%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nektar Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Summary

Nektar Therapeutics beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Nektar Therapeutics has a net margin of -287.84% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Nektar Therapeutics has lower revenue, but higher earnings than ImmunityBio. Nektar Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	75.31	-$351.40M	-$0.97	N/A
Nektar Therapeutics	$55.23M	44.83	-$164.08M	-$6.70	N/A

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 76.40%. Nektar Therapeutics has a consensus price target of $141.50, indicating a potential upside of 95.12%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Nektar Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 9 mentions for Nektar Therapeutics and 8 mentions for ImmunityBio. Nektar Therapeutics' average media sentiment score of 0.77 beat ImmunityBio's score of 0.61 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Nektar Therapeutics beats ImmunityBio on 11 of the 17 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.48B	$3.94B	$7.18B	$12.89B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-10.82	11.68	273.17	25.45
Price / Sales	44.83	1,408.89	638.21	103.75
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	16.44	16.92	11.08	6.36
Net Income	-$164.08M	-$22.74M	$3.48B	$349.79M
7 Day Performance	-1.59%	-0.13%	0.38%	-0.40%
1 Month Performance	2.62%	11.45%	7.89%	4.24%
1 Year Performance	142.87%	55.66%	24.71%	15.13%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTR Nektar Therapeutics	2.3264 of 5 stars	$72.52 flat	$141.50 +95.1%	+142.9%	$2.48B	$55.23M	N/A	220	Gap Up
CYTK Cytokinetics	2.8834 of 5 stars	$79.20 +2.2%	$102.20 +29.0%	+104.0%	$9.85B	$88.04M	N/A	250	Trending News Analyst Downgrade Gap Up
PTGX Protagonist Therapeutics	1.5846 of 5 stars	$151.50 +0.6%	$140.53 -7.2%	+144.4%	$9.80B	$46.02M	147.09	120	Positive News Gap Up
PCVX Vaxcyte	2.4406 of 5 stars	$61.09 flat	$86.00 +40.8%	+94.3%	$9.09B	N/A	N/A	160	Positive News Gap Up
IMVT Immunovant	1.4745 of 5 stars	$43.89 +0.9%	$44.00 +0.3%	+180.5%	$9.07B	N/A	N/A	120	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CYTK, PTGX, PCVX, IMVT, and IBRX

How does Nektar Therapeutics compare to Cytokinetics?

Summary

How does Nektar Therapeutics compare to Protagonist Therapeutics?

Summary

How does Nektar Therapeutics compare to Vaxcyte?

Summary

How does Nektar Therapeutics compare to Immunovant?

Summary

How does Nektar Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CYTK, PTGX, PCVX, IMVT, and IBRX

How does Nektar Therapeutics compare to Cytokinetics?

Do institutionals & insiders believe in NKTR or CYTK?

Which has preferable earnings and valuation, NKTR or CYTK?

Do analysts prefer NKTR or CYTK?

Is NKTR or CYTK more profitable?

Does the media refer more to NKTR or CYTK?

Which has more risk & volatility, NKTR or CYTK?

Summary

How does Nektar Therapeutics compare to Protagonist Therapeutics?

Which has more risk & volatility, PTGX or NKTR?

Do institutionals & insiders hold more shares of PTGX or NKTR?

Do analysts prefer PTGX or NKTR?

Is PTGX or NKTR more profitable?

Does the media refer more to PTGX or NKTR?

Which has preferable valuation and earnings, PTGX or NKTR?

Summary

How does Nektar Therapeutics compare to Vaxcyte?

Which has better valuation & earnings, PCVX or NKTR?

Which has more risk and volatility, PCVX or NKTR?

Does the media favor PCVX or NKTR?

Is PCVX or NKTR more profitable?

Do analysts recommend PCVX or NKTR?

Do institutionals & insiders believe in PCVX or NKTR?

Summary

How does Nektar Therapeutics compare to Immunovant?

Which has better earnings & valuation, NKTR or IMVT?

Does the media prefer NKTR or IMVT?

Is NKTR or IMVT more profitable?

Do analysts prefer NKTR or IMVT?

Do insiders and institutionals have more ownership in NKTR or IMVT?

Which has more risk & volatility, NKTR or IMVT?

Summary

How does Nektar Therapeutics compare to ImmunityBio?

Is IBRX or NKTR more profitable?

Which has more volatility & risk, IBRX or NKTR?

Which has better earnings & valuation, IBRX or NKTR?

Do analysts recommend IBRX or NKTR?

Do institutionals and insiders believe in IBRX or NKTR?

Does the media refer more to IBRX or NKTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools